Riya Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riya Patel has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Bhupendra Gopalbhai Prajapati
Parul University
5 shared publications - Shreeraj Shah
Department of Pharmaceutical Technology, LJ Institute of Pharmacy, LJ University Campus, Sarkhej, Ahmedabad, Gujarat, INDIA
4 shared publications Nehal Shah
School of Pharmacy, Indrashil University, Rajpur, Kadi, Gujarat, 382715, India
3 shared publications- Alkesh Patel
Charotar University of Science and Technology
2 shared publications - Gayatri Patel
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, India
2 shared publications - Omar Awad Alsaidan
Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia
2 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 328
Polymer-based Vaginal Insert Systems: Engineering Controlled Drug Delivery for Women’s Health
Polymer-based vaginal inserts have emerged as a promising approach for localized and systemic drug delivery, demonstrating improved therapeutic efficacy, p
- 15 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 328
Polymer-based Vaginal Insert Systems: Engineering Controlled Drug Delivery for Women’s Health
Polymer-based vaginal inserts have emerged as a promising approach for localized and systemic drug delivery, demonstrating improved therapeutic efficacy, p
- 4 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 266
Engineering Next-generation Drug Delivery Systems Via 4-D Printing: A Paradigm Shift Toward Precision Medicine
Four-dimensional (4-D) printed constructs have recently become clinically relevant platforms for customized and precise drug delivery due to their bio-prog
- 4 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 266
Engineering Next-generation Drug Delivery Systems Via 4-D Printing: A Paradigm Shift Toward Precision Medicine
Four-dimensional (4-D) printed constructs have recently become clinically relevant platforms for customized and precise drug delivery due to their bio-prog
- 8 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Functional Hybrid Wound Scaffolds for Controlled Drug Delivery and Smart Wound Management: A Decade of Progress
In order to avoid exogenous infections and promote healing, wound scaffolds (WS), an artificial barrier that separates the damaged location from the outside world, are a crucial part of wound care. Traditional wound dressings are widely used, although they have disadvantages such poor moisture retention and biocompatibility. Systems for scaffold-mediated delivery have developed as innovative ways to solve issues and improve patient outcomes. By enabling controlled and targeted drug delivery, they provide benefits in fostering an environment that is favorable for wound healing. The effectiveness of these systems for managing skin wounds can be increased by using functional wound scaffold (FWS) made from hybrid biological macromolecule-based materials. With an emphasis on hybrid biomaterials, methods, and applications developed within the previous decade years, the review seeks to give a broad overview of the most advanced FWS in the field of wound care. Furthermore, we emphasize the development of smart WS, the integration of biological macromolecules in WS. This study clarifies the promising potential of scaffold-mediated drug delivery in enhancing treatment outcomes and optimizing wound care practices through a synthesis of experimental results and recent literature. Furthermore, this review emphasizes the challenges and potential for the future of combining wound detection and therapy.
- 8 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Functional Hybrid Wound Scaffolds for Controlled Drug Delivery and Smart Wound Management: A Decade of Progress
In order to avoid exogenous infections and promote healing, wound scaffolds (WS), an artificial barrier that separates the damaged location from the outside world, are a crucial part of wound care. Traditional wound dressings are widely used, although they have disadvantages such poor moisture retention and biocompatibility. Systems for scaffold-mediated delivery have developed as innovative ways to solve issues and improve patient outcomes. By enabling controlled and targeted drug delivery, they provide benefits in fostering an environment that is favorable for wound healing. The effectiveness of these systems for managing skin wounds can be increased by using functional wound scaffold (FWS) made from hybrid biological macromolecule-based materials. With an emphasis on hybrid biomaterials, methods, and applications developed within the previous decade years, the review seeks to give a broad overview of the most advanced FWS in the field of wound care. Furthermore, we emphasize the development of smart WS, the integration of biological macromolecules in WS. This study clarifies the promising potential of scaffold-mediated drug delivery in enhancing treatment outcomes and optimizing wound care practices through a synthesis of experimental results and recent literature. Furthermore, this review emphasizes the challenges and potential for the future of combining wound detection and therapy.
- 21 April 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4) , 187
Formulation-Based Repurposing of Mifepristone Using a Drug-Eluting Intrauterine Insert for Localized Uterine Fibroid Therapy: A Preclinical Study
The majority of currently available treatments for uterine fibroids (UFs) are invasive and are delivered via either oral or parenteral means. Mifepristone
- 21 April 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4) , 187
Formulation-Based Repurposing of Mifepristone Using a Drug-Eluting Intrauterine Insert for Localized Uterine Fibroid Therapy: A Preclinical Study
The majority of currently available treatments for uterine fibroids (UFs) are invasive and are delivered via either oral or parenteral means. Mifepristone
- 24 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 159
3D Printed Vaginal Rings For Contraceptive Applications: Materials, Mechanisms, and Opportunities
Despite the wide range of contraception options available, half of births worldwide are still unplanned. Intravaginal rings (IVRs) have been a popular meth
- 24 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 159
3D Printed Vaginal Rings For Contraceptive Applications: Materials, Mechanisms, and Opportunities
Despite the wide range of contraception options available, half of births worldwide are still unplanned. Intravaginal rings (IVRs) have been a popular meth
- 21 March 2026
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 75 (9) , 986-1009
Chitosan-based nanocarriers: redefining targeted therapy for brain cancer
- 21 March 2026
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 75 (9) , 986-1009
Chitosan-based nanocarriers: redefining targeted therapy for brain cancer
- 10 March 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-25
Chitosan-based bioactive polymer systems for the treatment of vulvovaginitis: advances in vaginal drug delivery
Vulvovaginitis is an inflammation of the vulva and vagina that is commonly caused by yeast infections, bacterial vaginosis, or sexually transmitted illnesses affecting approximately 70-75% of women at least once during their lifetime, with recurrence rates reaching 30-40%. Vulvovaginal candidiasis (VVC) is an infection of the vulva and vagina caused by an overabundance of Candida yeast. Available therapy is not always effective, and resistance to several antifungal drugs therefore there is a need for advanced drug delivery systems. In recent decades, chitosan, a biopolymer having intrinsic antimicrobial activity (reported inhibition efficiencies exceeding 80-90% against Candida albicans), It has been considered as one of the most promising bioactive polymers; its antibacterial action, mucoadhesion, mucopenetration, immunomodulatory qualities, and longer drug retention have made it a potentially useful polymer. Chitosan-based vaginal delivery systems have demonstrated a 2-3-fold improvement in vaginal residence time and sustained drug release for up to 24-72 h. Which make this polymer ideal for the treatment of vaginitis. This review is looking at new drug delivery methods like hydrogels, films, and composite formulations for the treatment of vulvovaginitis. Furthermore, chitosan has been suggested as a bioactive polymer that may enhance current methods to develop hydrogels appropriate for VVC gynecological drug delivery systems. The shortcomings of conventional drugs, such as inadequate retention, systemic adverse effects, and drug resistance, demand more specific therapy options. Overall, chitosan-based systems represent a promising strategy for effective, safe, and targeted management of vulvovaginitis.
- 10 March 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-25
Chitosan-based bioactive polymer systems for the treatment of vulvovaginitis: advances in vaginal drug delivery
Vulvovaginitis is an inflammation of the vulva and vagina that is commonly caused by yeast infections, bacterial vaginosis, or sexually transmitted illnesses affecting approximately 70-75% of women at least once during their lifetime, with recurrence rates reaching 30-40%. Vulvovaginal candidiasis (VVC) is an infection of the vulva and vagina caused by an overabundance of Candida yeast. Available therapy is not always effective, and resistance to several antifungal drugs therefore there is a need for advanced drug delivery systems. In recent decades, chitosan, a biopolymer having intrinsic antimicrobial activity (reported inhibition efficiencies exceeding 80-90% against Candida albicans), It has been considered as one of the most promising bioactive polymers; its antibacterial action, mucoadhesion, mucopenetration, immunomodulatory qualities, and longer drug retention have made it a potentially useful polymer. Chitosan-based vaginal delivery systems have demonstrated a 2-3-fold improvement in vaginal residence time and sustained drug release for up to 24-72 h. Which make this polymer ideal for the treatment of vaginitis. This review is looking at new drug delivery methods like hydrogels, films, and composite formulations for the treatment of vulvovaginitis. Furthermore, chitosan has been suggested as a bioactive polymer that may enhance current methods to develop hydrogels appropriate for VVC gynecological drug delivery systems. The shortcomings of conventional drugs, such as inadequate retention, systemic adverse effects, and drug resistance, demand more specific therapy options. Overall, chitosan-based systems represent a promising strategy for effective, safe, and targeted management of vulvovaginitis.
- 23 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 344 (Pt 2) , 150488
Carboxymethyl chitosan for neurological drug delivery: Current trends and future prospects
- 23 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 344 (Pt 2) , 150488
Carboxymethyl chitosan for neurological drug delivery: Current trends and future prospects
- 4 August 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt B) , 110889
Inhibitors as a therapeutic frontier in lung cancer: Mechanism, opportunities, and molecular docking studies
- 4 August 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt B) , 110889
Inhibitors as a therapeutic frontier in lung cancer: Mechanism, opportunities, and molecular docking studies
- 18 May 2025
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-28
Whispers beneath the skin: how microneedles are shaping tomorrow’s therapies
Microneedles (MNs) offer a minimally invasive alternative to conventional patch-based and injection-based drug delivery methods. By bypassing first-pass metabolism and enhancing skin permeability, MNs significantly improve drug bioavailability. Their applications span vaccine administration, chronic disease management, and cosmetic treatments. Five major types of MNs have been identified, each with distinct mechanisms of action. Recent research focuses on advanced manufacturing techniques, stimuli-responsive materials, and combination drug therapies. Common materials include silicon, hydrogels, and biodegradable polymers, with growing interest in sustainable alternatives. Despite their potential, MNs face challenges related to drug stability, cost-effective production, and regulatory approvals. Emerging technologies, such as The integration of 3D printing, artificial intelligence, and biosensing technologies is driving significant advancements in personalized medicine. Clinical trials involving vaccines, biologics, and gene therapies are accelerating their path toward regulatory acceptance. MNs support patient self-administration, reduce dependency on healthcare infrastructure, and expand global access to treatment. Their integration with telemedicine and remote drug monitoring positions them as a transformative tool in future medical practice.
- 18 May 2025
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-28
Whispers beneath the skin: how microneedles are shaping tomorrow’s therapies
Microneedles (MNs) offer a minimally invasive alternative to conventional patch-based and injection-based drug delivery methods. By bypassing first-pass metabolism and enhancing skin permeability, MNs significantly improve drug bioavailability. Their applications span vaccine administration, chronic disease management, and cosmetic treatments. Five major types of MNs have been identified, each with distinct mechanisms of action. Recent research focuses on advanced manufacturing techniques, stimuli-responsive materials, and combination drug therapies. Common materials include silicon, hydrogels, and biodegradable polymers, with growing interest in sustainable alternatives. Despite their potential, MNs face challenges related to drug stability, cost-effective production, and regulatory approvals. Emerging technologies, such as The integration of 3D printing, artificial intelligence, and biosensing technologies is driving significant advancements in personalized medicine. Clinical trials involving vaccines, biologics, and gene therapies are accelerating their path toward regulatory acceptance. MNs support patient self-administration, reduce dependency on healthcare infrastructure, and expand global access to treatment. Their integration with telemedicine and remote drug monitoring positions them as a transformative tool in future medical practice.